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ABSTRACT
Donor bone marrow (BM)–derived CD4CD25 regulatory T cells, maturing in the host thymus, are critical
in inhibiting graft-versus-host disease (GVHD) after donor lymphocyte infusion (DLI) in murine BM chime-
ras. Data presented here demonstrate that fresh CD25 cells isolated from donor-type mice can be expanded
ex vivo by a variety of methods. Ex vivo–expanded CD4CD25 and CD8CD25 cells were potent suppres-
sors of donor response to host alloantigens in mixed lymphocyte reaction assays. Both fresh and ex vivo–
expanded CD4CD25 cells persisted long-term in vivo and effectively prevented DLI-induced GVHD in
CD25/ BM chimeras. Importantly, co-infused CD4CD25 cells with DLI cells migrated to peripheral
lymphoid organs and survived long-term in DLI-treated CD25/ chimeras, but not in DLI-treated CD25/
chimeras, indicating homeostatic control of CD25 cells and an available niche required for their long-term
persistence. Furthermore, maintenance of CD25 expression seemed necessary for suppressive function,
because only the CD25 cell fraction, but not the CD25 fraction isolated after adoptive transfer, was
suppressive in vitro. Ex vivo–expanded CD8CD25 cells weakly prevented GVHD, apparently because of a
rapid disappearance of these cells after adoptive transfer. Taken together, these data suggest that the
therapeutic use of ex vivo–expanded CD4CD25 cells may be a feasible, nontoxic modality for controlling
GVHD in the clinic. Because of strict homeostatic control, an available niche may be required for long-term
persistence of infused regulatory T cells.
© 2004 American Society for Blood and Marrow Transplantation
KEY WORDS
Donor lymphocyte infusion ● Graft-versus-host disease ● Bone marrow transplantation ●
Regulatory T cells ● CD4CD25 ● CD8CD25
r
a
l
n
o
f
H
t
f
tNTRODUCTION
Generation of immune suppressor T (Ts) cells
fter bone marrow transplantation (BMT) has long
een proposed to participate in the establishment and
aintenance of donor-host tolerance [1]. Ts cells have
een documented in various rodent tissue and organ
ransplantation models since the early 1970s [2,3]. In
xperimental and clinical BMT settings, Ts cell activ-
ty has repeatedly been demonstrated in donor/recip-
ent mixed lymphocyte reaction (MLR) assays. In the
arly 1980s, Tutschka and Santos [4] systematically
haracterized the kinetics and speciﬁcity of bone mar- (
48ow (BM)-derived Ts cells after BMT in rats. Char-
cteristics of those Ts cells included alloantigen (al-
oAg)–dependent generation and maintenance; both
on–alloAg-speciﬁc and alloAg-speciﬁc development
f suppressive activity; and passage of suppression
rom BMT recipients to naive rats by T-cell transfer.
owever, the absence of speciﬁc and reliable markers
o discriminate Ts cells from other T cells prevented
urther characterization of these Ts cells.
Previous studies from our group have shown
hat donor BM-derived  T-cell receptor
TCR)CD3T cells, including CD4CD8 and
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Ex Vivo–Expanded CD4CD25 and CD8CD25Treg Cells in GVHD
BD4CD8 subsets, maturing in the host thymus
re capable of inhibiting the development of graft-
ersus-host disease (GVHD) after delayed donor
ymphocyte infusion (DLI) in allogeneic murine
M chimeras [5]. Further studies showed that do-
or BM-derived CD4CD25 cells are one of the
rincipal Ts populations responsible for controlling
VHD initiated by DLI [6]. Interestingly, a popu-
ation CD4 cells coexpressing CD25 was shown in
990 to be a primary mediator of cardiac graft
olerance in rats [7]. As the result of the seminal
ork by Sakaguchi et al. [8], CD4CD25 cells
ere shown to comprise a population of highly
otent Ts cells. These Ts cells are now typically
eferred to as regulatory T (Treg) cells. Recently,
everal studies have shown that CD4CD25 cells
an effectively suppress GVHD and graft rejection
nd facilitate the induction and maintenance of
ransplantation tolerance [9-17].
Strategies for inducing transplantation tolerance
ave recently focused on the generation or expansion
f alloAg-speciﬁc CD4CD25 cells. Examples of
uch strategies include using monoclonal antibodies
mAb) speciﬁc for CD3, CD4, or CD154; a combina-
ion of 1,25-dihydroxyvitamin D3 with mycopheno-
ate mofetil; pretransplantation donor blood transfu-
ion; and administration of tolerogenic or regulatory
endritic cells [16,18-23]. Also, a series of recent stud-
es have clearly shown that it is possible to generate
ntigen-speciﬁc CD4CD25 clones in vitro and
n vivo [24-28]. Furthermore, other recent studies
ave demonstrated that fresh or ex vivo–activated
D4CD25 T cells can prevent the development of
VHD and inhibit cardiac graft rejection in murine
odels [9-14,17,29]. However, tracking and persis-
ence of the adoptively transferred CD4CD25 cells
as not investigated in these studies.
For ex vivo–generated CD4CD25 T cells to be
sed as clinical treatment for GVHD or autoimmune
isease, the following cell properties would likely be
ecessary: sufﬁcient numbers of cells, migration in
ivo to sites of antigen reactivity, ability to suppress
mmune reactivity in an antigen-speciﬁc manner, and
urvival after infusion for some unknown period of
ime. To examine these issues, this study was aimed at,
rst, deﬁning efﬁcient methods for ex vivo expansion
f CD4CD25 cells, because these cells are a rare
ell population and are highly anergic to in vitro
timuli [29-31]. Second, we examined the suppressive
unction of fresh and ex vivo–expanded CD4CD25
nd CD8CD25 cells towards alloAgs in vitro.
hird, we studied in vivo dynamics of fresh and ex
ivo–expanded CD25 cells after adoptive transfer
nto syngeneic or allogeneic nude mice. Finally, im-
une-suppressive effects and in vivo persistence of
resh and ex vivo–expanded CD4CD25 and
D8CD25 cells were investigated after transfer t
B&MTnto Treg-deﬁcient CD25 knockout (KO; CD25
/)
M chimeras undergoing lethal acute GVHD after
LI therapy.
ATERIALS AND METHODS
ice
The following strains of mice, 6 to 8 weeks of age,
ere purchased from Jackson Laboratories (Bar Har-
or, ME): C57BL/6 (B6; H-2b; Thy1.2), congenic
6.PL-Thy1a (H-2b; Thy1.1), AKR/J (H-2k;
hy1.1), AKR/Cum (H-2k; Thy1.2), B6 nude
B6.Cg-Foxn1nu), BALB/c nude (CByJ.Cg-Foxn1nu/J;
-2d;Thy1.2), and B6 CD25 KO (C57BL/6-
L2rarm/Dw; H-2b; Thy1.2) heterozygote (CD25/)
reeders. AKR/Cum mice and CD25 KO homozy-
otes (CD25/) were bred in-house, and all F(1)
ittermates derived from CD25 KO breeding pairs
ere screened for homozygosity by using polymerase
hain reaction methods as suggested by the vendor.
ll mice were housed and cared for in the Medical
ollege of Wisconsin’s Biomedical Resource Center
Milwaukee, WI).
eagents and Antibodies
The following mAbs were purchased from BD
harmingen (San Diego, CA): puriﬁed and ﬂuorescein
sothiocyanate (FITC)–conjugated hamster anti-
ouse CD3ε (clone 145-2C11), allophycocyanin
APC)–conjugated rat anti-mouse CD4 (clone RM4-
), Cy-Chrome–conjugated rat anti-mouse CD8a
clone 53-6.7), phycoerythrin (PE)–conjugated rat an-
i-mouse CD25 (clone PC61), FITC-conjugated rat
nti-mouse CD25 (clone 7D4), FITC-conjugated
ouse anti-rat CD90/mouse CD90.1 (Thy1.1; clone
IS51), PE-conjugated rat anti-mouse CD90.2
Thy1.2; clone 53-2.1), puriﬁed hamster anti-mouse
D28 (clone 37.51), and FITC-conjugated rat anti-
ouse 4-1BB (clone 1AH2). In vivo–depleting anti-
D25 (clone PC61) and anti-Thy1.2 (clone 53-2.1)
Ab-producing hybridoma cells were obtained from
he American Type Culture Collection (Bethesda,
D). These mAbs were produced in our laboratory
y using a Vivascience bioreactor system (Hanover,
ermany). Rabbit anti-asialo GM1 serum was pur-
hased from Wako Pure Chemical Industry, Ltd.
Osaka, Japan). Collagenase D was obtained from
oche Applied Sciences (Indianapolis, IN). Recombi-
ant human interleukin (IL)–2 was provided by the
CI Biological Resources Branch (Rockville, MD).
ovine serum albumin (BSA) and 2-mercaptoethanol
ere obtained from Sigma (St. Louis, MO). Fetal
ovine serum (FBS), phosphate-buffered saline (PBS),
igh-glucose Dulbecco modiﬁed Eagle medium
DMEM), HEPES buffer, sodium pyruvate, l-glu-
amine, l-arginine, l-asparagine, folic acid, nonessen-
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7ial amino acids, and penicillin/streptomycin were ob-
ained from Invitrogen (Carlsbad, CA).
D25 Cell Isolation
Single cells from B6 or B6.PL spleen and lymph
odes were enriched for T cells by using nylon wool
ber columns (Polysciences, Inc., Warrington, PA), and
he nylon wool-enriched T cells were stained with PE/
nti-CD25 mAb for 30 minutes on ice (0.1 g/106 cells).
fter washing with 0.5% BSA/PBS, the cells were resus-
ended in 0.5% BSA/PBS and incubated with anti-PE–
onjugated microbeads (1 L/106 positive cells; Miltenyi
iotec Inc., Auburn, CA) for 15 minutes at 4°C. CD25
ells were isolated with an automated magnetic cell
orter (AutoMACS; Miltenyi Biotec). With this strategy,
D25 cell purity was 98%.
x Vivo CD25 Cell Expansion
Two methods were used to expand CD25 cells ex
ivo.
Method I. Ninety-six–well round-bottom plates
ere coated with anti-CD3ε mAb diluted in PBS (50
L per well) at 4°C overnight. Freshly isolated
D25 cells were suspended in complete DMEM
10% FBS, 1 mmol/L sodium pyruvate, 10 mmol/L
EPES buffer, 0.05 mmol/L 2-mercaptoethanol, 2
mol/L l-glutamine, 69 mmol/L l-arginine, and 100
/mL penicillin/streptomycin) containing 100 U/mL
L-2 and 4 g/mL anti-CD28 mAb. Aliquots of the
ell suspension were cultured in anti-CD3ε–coated
ells at ﬁnal concentrations of 5 to 10  104 cells per
ell (200 L per well). In selected experiments, irra-
iated (3000 rad) allogeneic strain AKR splenocytes
ere added as stimulators to the CD25 cells. Specif-
cally, irradiated CD11c-enriched AKR splenocytes (3
105 per well) were cocultured with 105 fresh
D25 cells with or without IL-2 and/or anti-CD3/
D28 mAbs.
Method 2. An established artiﬁcial antigen-pre-
enting cell (aAPC) system—ie, a CD32 and 4-1BB
igand (4-1BBL) double-transfected K562 tumor cell
ine—has been described previously [32]. The ratio-
ale for using this system is that aAPCs loaded with
nti-CD3ε and anti-CD28 mAb via CD32 molecules
rovide additional co-stimulatory signaling through
-1BB ligation on CD25 T cells [33]. The aAPCs
ere coated with anti-CD3ε (10 g/mL) and anti-
D28 (4 g/mL) mAb for 30 minutes in complete
MEM at room temperature. The cells were then
rradiated (10000 rad) before coculture with fresh
D25 cells in 100 U/mL IL-2 at a ratio of 1:2
CD25/aAPC) in 96-well plates.
CD25 cells expanded by the various methods
ere checked daily and split with fresh IL-2–contain-
ng media to maintain the cells at a concentration of
.5 to 1  106/mL. After 5 days of culture in 96-well a
50lates, the CD25 cells were transferred to ﬂasks for
urther culture. Ex vivo–expanded CD25 cells were
henotyped by ﬂow cytometry, assayed for suppres-
ive activity in vitro, or used for adoptive transfer in
ivo.
n Vitro Suppression Assays
Fresh and ex vivo–expanded CD25 cells, includ-
ng puriﬁed CD4CD25 and CD8CD25 cells
separated by magnetically activated cell sorting after
ulture) and CD4CD8CD25 cells (isolated by
ow cytometric sorting after culture), were assayed for
uppressive activity in allogeneic MLR assays. To as-
ay the in vitro suppressive activity of CD25 and
D25 fractions of infused CD4CD25 cells (iso-
ated from both adoptively transferred B6 nude and
D25/ chimeric mice) and in vivo–expanded CD8
ells (isolated from adoptively transferred B6 nude mice
nly), Thy1.1CD4CD25, Thy1.1CD4CD25,
nd Thy1.1CD8 cells were sorted by ﬂow cytometry
y using the following panel of mAbs: anti-Thy1.1
ITC, anti-CD25 PE, anti-CD8 Cy-Chrome, and anti-
D4 APC. Irradiated (3000 rad) AKR CD11c-enriched
plenocytes, supplemented with irradiated CD11c-de-
leted splenocytes, were used as allogeneic stimulators (3
105 per well) in 96-well round-bottom plates. CD25-
epleted (using an AutoMACS) naive B6 or B6.PL T
ells were used as responder cells (105 per well). Variable
umbers of CD25 cells were added to a ﬁxed number
f responder cells and stimulator cells, and the CD25
reg/CD25
 responder ratios ranged from 1:1 to 1:128.
fter 4 days in culture, 3H-thymidine was added to each
ell for an additional 18 hours. 3H-Thymidine incorpo-
ation was measured on a -scintillation counter, and the
esults were expressed as counts per minute (CPM).
ells without CD25 cells (responders and stimulators
nly) served as positive controls (ie, maximum CPM).
ells containing different dilutions of CD25 cells and
timulator cells (no responders) served as baseline con-
rols (ie, baseline CPM). Suppression was expressed as
ercentage of control MLR by using the following for-
ula: [experimental CPM (wells containing CD25
ells)  baseline CPM]/maximum CPM. The ratio of
D25 Treg to CD25
 responder T cells to achieve
0% suppression or inhibition (ID50) of control MLR
as calculated with a linear regression method.
doptive Transfer of CD25 Cells into Nude Mice
Fresh or ex vivo–expanded CD25 cells (5  106)
ere injected intravenously (IV) on day 0 into syngeneic
6 nude mice or natural killer (NK) cell–depleted allo-
eneic BALB/c nude mice. NK cell depletion was
chieved by 5 consecutive injections of 50 L of anti-
sialo GM1 antibodies on days 2, 0, 2, 4, and 7.
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Ex Vivo–Expanded CD4CD25 and CD8CD25Treg Cells in GVHD
Bone Marrow Transplantation
Host AKR/cum mice were lethally irradiated with
100 cGy 1 day before BMT. To help prevent graft
ejection, a single intraperitoneal (IP) injection of 500
g of anti-Thy1.2 mAb was given on the day of
ransplantation. A total of 107 fresh BM cells, har-
ested from CD25/, CD25/, or CD25/ B6
onor mice, were injected IV via the tail veins. BM
ngraftment was conﬁrmed by ﬂow cytometry at 3
eeks after BMT.
VHD Induction
GVHD was induced at 4 weeks after BMT in
D25/, CD25/, and CD25/ BM chimeras by
V infusion of 5  106 CD25-depleted T cells (ie,
LI). In selected animals, fresh or ex vivo–expanded
D4CD25 or CD8CD25 cells, at CD25/
D25 ratios of 1:1 (5  106 CD25) or 2:1 (2.5 
06 CD25) were co-infused with the DLI. In some
D25/ BM chimeras, mice were injected IP with
nti-CD25 mAb at 7 days (500 g per mouse) and 4
ays (250 g per mouse) before DLI. In these exper-
ments, DLI cells consisted of 3  107 normal or in
ivo–CD25-depleted (ie, treated with anti-CD25
Ab) B6 or B6.PL splenocytes. Approximately 70%
f CD25 cells were depleted by in vivo treatment
ith anti-CD25 mAb, and the CD25 cells recovered
o normal levels within 10 to 14 days after the last
njection of anti-CD25 mAb.
ell Tracking and Phenotypic Analysis
Infused fresh or ex vivo–expanded CD25 cells
rom B6.PL mice (Thy1.1) were monitored for in
ivo persistence and CD25 expression for 6 months in
yngeneic B6 (Thy1.2) nude mice and allogeneic
ALB/c (Thy1.2) nude mice. Similarly, by using
D25 cells from Thy1.1 B6.PL mice and DLI cells
rom Thy1.2 B6 mice, infused CD4CD25 or
D8CD25 cells were followed for persistence and
D25 expression in CD25/ or CD25/ B6-into-
KR/Cum (Thy1.2) BM chimeras for 15 weeks.
eripheral blood mononuclear cells and cells from
able 1. Ex Vivo Expansion of Total CD25 Cells
Stimulation*
CD3CD2
AlloAgs 0.35  0.1
IL-2 (100 U/mL) 1.56  0.2
IL-2/alloAgs 2.43  0.5
Anti-CD3/CD28 Cells die
Anti-CD3/CD28/alloAgs 0.70  0.1
Anti-CD3/CD28/IL-2 13.5  6.2
Anti-CD3/CD28/IL-2/alloAgs 23.4  14
The starting cell number for each culture was 2  106 freshly isolated
The averages 	 SD are the combined results of 6 experiments.pleen and lymph nodes were stained with the follow- t
B&MTng panel of cell-surface markers: anti-Thy1.1 FITC,
nti-CD25 PE, anti-CD8 Cy-Chrome, and anti-CD4
PC. The samples were analyzed on a Becton Dick-
nson FACSCalibur ﬂow cytometer (San Jose, CA).
tatistics
Survival curves were compared by log-rank anal-
sis. Signiﬁcance was deﬁned as P .05.
ESULTS
x Vivo Expansion of CD25 T Cells (CD4,
D8, and CD4CD8 Subsets) by Using
nti-CD3 and Anti-CD28 mAb
Most (90%) freshly isolated natural CD25 T
ells were CD4; however, the CD25-enriched cells
lso contained small percentages of CD8CD25
1%–3%) and CD3CD4CD8CD25 (2%–4%)
cells. As shown in Table 1, freshly isolated
D4CD25 cells were expanded only when acti-
ated through the TCR and CD28 pathways in the
resence of IL-2; alloAgs alone or alloAgs plus IL-2
ailed to expand the CD4CD25 population. In the
resence of IL-2, the small numbers of CD8CD25
ells rapidly expanded in culture and became the dom-
nant cell population. Overgrowth by CD8CD25
ells was not the main reason for poor expansion of
D4CD25 cells cultured with plate-bound anti-
D3, because removal of CD8 cells from total
D25 cells on days 3 to 5 in culture did not mark-
dly enhance expansion of CD4CD25 cells (data
ot shown).
To achieve better ex vivo expansion of
D4CD25 cells, CD32/4-1BBL–transfected K562
ells were used as aAPC. Through loading of anti-
D3 and anti-CD28 mAb onto transfected CD32
olecules, a preferential (90%–95% CD4) and
arked expansion of CD4CD25 cells (10- to 15-
old between days 7 and 10 of culture) was ob-
ained (Table 2). Ligation of 4-1BBL on aAPC to
-1BB on CD4CD25 cells was important, because
D32-transfected K562 aAPC (no 4-1BBL transfec-
-Fold Expansion after 1 wk†
CD4CD25 CD8CD25
0.27  0.08 0.29  0.12
0.09  0.06 50.4  6.21
0.42  0.24 66.8  7.73
Cells died Cells died
0.61  0.20 1.89  0.44
3.75  3.04 301.2  14.2
5.98  3.42 356.1  67.5
 cells; see Materials and Methods for details.5
2
1
1
d
8
0
.26
CD25ion) loaded with anti-CD3/CD28 mAb failed to in-
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7uce signiﬁcant expansion of CD4CD25 cells (less
han 3- to 5-fold by day 10; data not shown).
x Vivo–Expanded CD4CD25 and CD8CD25
ells, but Not CD4CD8CD25 T Cells, Were
uppressive in MLR Assays
As shown in Figure 1A and B, activated/expanded
D25 T cells exerted stronger suppression (ID50
as between 1:10 and 1:25) in MLR assays than fresh
D25 T cells (ID50, 1:1), regardless of the activation
ignals, including alloAgs or anti-CD3/CD28 mAb.
D25 T-cell subsets expanded in culture were
orted into CD4CD25, CD8CD25, and
D4CD8CD25 subsets by ﬂow cytometry by us-
ng the following panel of mAbs: anti-CD3 FITC,
able 2. Ex Vivo CD4CD25 Cell Expansion
Stimulation*
Plate-bound anti-CD3/soluble anti-CD28/IL-2
Plate-bound anti-CD3/soluble anti-CD28/IL-2/alloAgs
Anti-CD3/CD28-coated K562 aAPC/IL-2
The starting cell number for each culture was 2  106 freshly isolated C
expanded CD4CD25 cells.
The data (averages 	 SD) are the combined results of 6 experiments.
igure 1. Fresh and ex vivo–expanded CD25 T cells were suppre
nti-CD3/CD28 mAbs, or combinations of these stimuli (A and
D4CD8 subsets (C), were assayed for suppressive activity in M
o the assays. All curves are expressed as percentage of control M
xperiments. The raw data values for the control MLRs ranged from 10 t
52nti-CD25 PE, anti-CD4 APC, and anti-CD8
y-Chrome. CD4CD25 (ID50, 1:10) and
D8CD25 (ID50, 1:10) cells, but not CD4
CD8
ells, were potently suppressive in vitro (Figure 1C).
he in vitro suppressive function of CD8CD25
ells was not overcome by the addition of 100 U/mL
f exogenous IL-2 to the MLR assay (Figure 1D).
resh or Ex Vivo–Expanded CD4CD25 Cells
roliferated and Trafficked through the Peripheral
ymphoid Tissues In Vivo after Adoptive Transfer
nto Syngeneic or Allogeneic Nude Mice
Fresh CD4CD25 and CD8CD25 cells not
nly expanded ex vivo, but also seemed to proliferate
n vivo after adoptive transfer into nude recipient
-Fold Expansion†
Day 7 Day 10 Day 14
3.8  3.0 6.2  2.2 2.1  1.5
5.9  3.4 10  3.5 4.9  2.9
13.1  2.9 12.7  4.4 7.3  2.4
cells; see Materials and Methods for details. K562 aAPCs preferentially
vitro. Fresh CD25 cells, CD25 cells activated by alloAgs, IL-2,
well as ex vivo–expanded CD3CD25 or CD4, CD8, and
says. In some experiments (D), exogenous IL-2 was added directly
d represent the combined average values of 10 to 15 individualD25ssive in
B), as
LR as
LR ano 15  104 CPM.
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Ex Vivo–Expanded CD4CD25 and CD8CD25Treg Cells in GVHD
Bice. As shown in Figure 2A, freshly isolated
hy1.1CD25 cells (5  106 injected) could be
etected in peripheral lymphoid organs, including the
eripheral blood, spleen, and lymph nodes, after
doptive transfer into syngeneic B6 nude mice
Thy1.2). Interestingly, only 20% to 30% of the
njected CD4CD25 and less than 3% to 5% of the
D8CD25 cells maintained CD25 expression in
yngeneic nude recipients (Figure 2B). Both fresh and
x vivo–expanded Thy1.1CD4CD25 cells per-
isted and survived more than 6 months in peripheral
lood after adoptive transfer into Thy1.2 syngeneic
6 or NK cell–depleted allogeneic BALB/c nude re-
ipients (Figure 2c). No homing capacity impairment
as apparent: both fresh and ex vivo–expanded
D4CD25 cells persisted in the peripheral lym-
hoid organs equally well (Figure 2C). CD25 expres-
ion on fresh or expanded CD4CD25 cells was
aintained on higher percentages of cells (60%–80%)
n allogeneic nude recipients as compared with synge-
eic nude recipients (20%–30%, Figure 2D).
ermanent Absence or Temporary Depletion of
onor BM-Derived CD25 Cells Increased the
everity of GVHD after DLI
Wild-type (CD25/) and CD25 KO heterozy-
igure 2. Fresh and ex vivo–expanded CD25 cells could be detecte
he peripheral blood of syngeneic B6 or allogeneic BALB/c nud
ivo–expanded CD4CD25 cells (C and D) was analyzed at var
aintenance of CD25 expression on infused cells (B and D). At 24
pleen (SP), and lymph node (LN) were analyzed by ﬂow cytome
yngeneic B6 nude recipients given fresh (n 
 5; A-D) or ex vivo
llogeneic BALB/c nude recipients infused with fresh (n 
 5; C anote (CD25/) BM chimeras were resistant to DLI- i
B&MTnduced GVHD (Figure 3A). In contrast, the com-
lete absence of CD25 molecules (CD25/ bone
arrow chimeras) on donor BM-derived T cells re-
ulted in lethal acute GVHD after DLI with 5  106
D3CD25 T cells given 4 weeks after BMT (P
.000005; Figure 3A). The severity of GVHD was
eﬂected by acute body weight loss (Figure 3B). Acute
nd lethal GVHD were also seen in CD25/ BM
himeras that had been temporarily depleted of
D25 cells in vivo (by treatment with anti-CD25
Ab) before DLI at doses of 3  107 (Figure 3C) or
 107 (Figure 3D) splenocytes. Depletion of CD25
ells from the DLI inoculum did not increase the
everity of GVHD in untreated or anti-CD25–treated
osts (Figure 3C and D). BMT controls (CD25/,
D25/, and CD25/) without DLI therapy (n 

for each group) all survived long-term, but the data
re not shown in Figure 3.
resh or Ex Vivo–Expanded CD4CD25 Cells
revented Lethal Acute GVHD after Cotransfer
ith DLI
As previously shown in Figure 3, 5  106
D25CD3 T cells given as DLI at 4 weeks after
MT induced lethal acute GVHD in CD25/ BM
himeras. GVHD was signiﬁcantly inhibited by co-
term after adoptive transfer into syngeneic or allogeneic nude mice.
ient mice given fresh Thy1.1 B6.PL CD25 cells (A-D) or ex
e points for the presence of infused cells (A and C) and for the
after transfer, all mice were killed, and the peripheral blood (PB),
lysis of gated lymphocytes. The results are the combined data of
ded CD4CD25 cells (n 
 5; C and D) or NK cell–depleted
r ex vivo–expanded CD4CD25 cells (n 
 5; C and D).d long-
e recip
ious tim
week
tric ana
–expannfusion of CD25/ BM chimeras with fresh (Figure
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7A) or ex vivo–expanded (Figure 4B) CD4CD25
ells at doses of 5  106 (CD25/CD25 cell ratio of
:1) or 2.5  106 (CD25/CD25 cell ratio of 2:1)
ells. The BM chimeras co-infused with fresh or ex
ivo–expanded CD4CD25 cells were healthy more
han 15 weeks after DLI, with little or no body weight
oss (Figure 4C and D) or any other signs of acute or
hronic GVHD.
x Vivo–Expanded CD8CD25 T Cells Weakly
uppressed Acute GVHD Compared with
x Vivo–Expanded CD4CD25 Cells
Compared with ex vivo–expanded CD4CD25
ells, ex vivo–expanded CD8CD25 cells were rel-
tively inefﬁcient at suppressing lethal acute GVHD
n CD25/ BM chimeras given 5  106 CD25 T
ells as DLI (Figure 5). Thirty percent of mice co-
nfused with 5  106 CD8CD25 cells (CD25/
D25 cell ratio of 1:1) survived 15 weeks after DLI,
hich was signiﬁcantly better than survival of the
oninfused DLI control mice (P
 .005). The onset of
VHD was paralleled by body weight loss (Figure
B). A lower dose of 2.5  106 CD8CD25 cells
CD25/CD25 cell ratio of 2:1) failed to protect any
igure 3. CD25/ BM chimeras or normal BM chimeras depleted
verage body weights (B) for CD25/ (n 
 10), CD25/ (n 
 1
106 CD3CD25 T cells. In (C) and (D), untreated or in vivo C
undepleted DLI) or CD25-depleted splenocytes (CD25-depleted D
xperiments, a total of 11 to 12 mice for each experimental DLI g
xperiments. The CD25-depleted, no-DLI control group in (C)
D25/), composed of 3 to 5 animals for each group without DLD25/ BM chimeras from DLI-induced GVHD m
54Figure 5A), and survival of these mice was not signif-
cantly different from that of DLI controls (P 
 .07).
resh and Ex Vivo–Expanded CD4CD25
urvived Long-term and Trafficked to Lymphoid
issues during Suppression of Lethal Acute
VHD, but Ex Vivo–Expanded CD8CD25
isappeared within 2 to 3 Weeks after Infusion
Fresh and ex vivo–expanded Thy1.1CD4CD25
ells co-infused with DLI (Thy1.2) into CD25/
M chimeras (Thy1.2) persisted and survived
qually well in peripheral blood and migrated through
eripheral lymphoid organs during suppression of
VHD (Figure 6A). Stable percentages of
D4CD25 cells were observed in peripheral blood
0.5%–1% of peripheral blood mononuclear cells),
nd higher percentages were present in the spleen and
ymph nodes (1.5%–3%) at 15 weeks after infusion.
oth fresh and ex vivo–expanded CD4CD25 cells
aintained CD25 expression on 50% to 70% of the
doptively transferred cells (Figure 6B). High percent-
ges of adoptively transferred cells (60%–80%) found
n the spleen and lymph node at 15 week after infusion
lso maintained CD25 expression (Figure 6B). Re-
25 cells developed lethal GVHD after DLI. The survival (A) and
D25/ (n 
 15) BM chimeras were monitored after DLI with 5
pleted CD25/ chimeras were given DLI with whole splenocytes
doses of 3  107 (C) or 6  107 (D) cells. In the CD25 depletion
ere analyzed, representing the combined data from 3 independent
) consisted of 3 mice. BMT controls (CD25/, CD25/, and
py, were followed up long-term but not shown on Figure 3.of CD
0), or C
D25-de
LI) at
roup w
and (Darkably, ex vivo–expanded CD4CD25 cells could
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Ex Vivo–Expanded CD4CD25 and CD8CD25Treg Cells in GVHD
Be readily detected in CD25/ BM chimeras but
ere nearly undetectable in CD25/ BM chimeras
uring the entire experimental period (Figure 7), in-
icating that adoptively transferred CD4CD25
ells failed to persist in mice that had reconstituted
heir CD25 cell compartment. In contrast to ex vivo–
xpanded CD4CD25 cells, ex vivo–expanded
D8CD25 cells typically disappeared within 2 to 3
eeks after co-infusion with DLI into CD25/ BM
himeras (Figure 8).
nly Cells That Maintained CD25 Expression after
doptive Transfer Were Suppressive In Vitro
As noted previously, 2 populations (CD4 and
D8) of CD25 cells expanded after adoptive trans-
er into syngeneic nude mice, and more than half of
he CD4CD25 cells lost CD25 expression. At 6
onths after adoptive transfer, the CD4 and CD8
ells were reisolated from spleen and lymph node by
ow cytometric sorting based on CD25 expression
nd assayed for suppressive activity in vitro by using
aïve B6 CD25 T cells as responders and CD11c-
nriched naïve AKR/J splenocytes as stimulators. Un-
xpectedly, only the CD4CD25 cells were still sup-
ressive in MLR assays (Figure 9A); the CD4CD25
nd CD8 cells either enhanced or failed to suppress
LR reactivity. CD25 and CD25 fractions of in-
igure 4. Adoptively transferred fresh or ex vivo–expanded dono
D25/ BM chimeras. Survival graphs (A and B) and body weigh
) or ex vivo–expanded CD25 cells (B and D) at the time of DL
x vivo–expanded CD25 cells were given at CD25/CD25 cell
xpanded). Controls consisted of CD25/ BM chimeras given DLused CD4CD25 cells were also isolated from the m
B&MTpleen and lymph node by ﬂow cytometric sorting
rom DLI-treated CD25/ chimeric mice at 15
eeks after DLI and tested for suppressive activity in
LR assays. Again, only the CD25 fraction of cells
uppressed MLR reactivity (Figure 9B).
ISCUSSION
Among a variety of Ts or Treg cell populations,
D4CD25 Treg have been well characterized in
he suppression of autoimmunity, prevention of
VHD and graft rejection, and induction of trans-
lantation tolerance, as well as downregulation of im-
une responses against tumors and microbes
3,29,30,34]. On the basis of their potent suppressive
ctivity, therapeutic administration of CD4CD25
ells may be a viable approach to controlling GVHD
nd graft rejection or even inducing permanent trans-
lantation tolerance without eliminating beneﬁcial
ntitumor effects [12,13]. These cells may also help to
romote BM engraftment and thereby enhance im-
une reconstitution after BMT [13,35]. However, it
s essential to understand several unknown aspects of
D4CD25 cells before clinical use, including how
hese cells trafﬁc after adoptive transfer and whether
hey persist, or how long they need to persist, to
5 cells suppressed the development of DLI-induced GVHD in
s (C and D) are shown for CD25/ chimeras given fresh (A and
106 CD25 T cells given 28 days after transplantation). Fresh and
f 1:1 (n 
 9 mice per group) or 2:1 (n 
 11 for fresh; n 
 8 for
out co-infusion of CD25 cells (n 
 15).r CD2
t curve
I (5 
ratios oediate their function. For example, can these cells be
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7fﬁciently expanded ex vivo and still maintain their
uppressive activity? Ex vivo expansion may be neces-
ary because CD4CD25 cells are present in fresh
ymphoid tissues at very low numbers [3,29,30]. Is
ystemic immune suppression after adoptive transfer a
oncern, or do these cells suppress antigen reactivity
n a speciﬁc manner? In vitro data suggest that once
D25 Treg become activated, their suppression is
ntigen nonspeciﬁc [31]. However, recent data have
uggested that CD25 Treg can suppress antigen re-
ctivity in vivo in an antigen-speciﬁc manner [36].
Besides naturally occurring CD4CD25 cells,
here are low numbers of CD8 (1%–3% of total
D25 cells) and CD4CD8 (2%–4% of total
D25 cells) cells in normal mice that coexpress
D25. After triggering the TCR and CD28 cosignal-
ng pathways, all subsets of CD25 cells are expand-
ble, particularly CD4CD25 and CD8CD25
ells. Culture with plate-bound anti-CD3 and soluble
nti-CD28 mAb was inefﬁcient for expansion of the
D4 subset from puriﬁed CD25 cells. First, over-
rowth of CD8CD25 cells inhibited expansion of
D4CD25 cells with this strategy. Second, no sig-
iﬁcant improvement in expansion was observed when
he CD4 fraction of CD25 cells was puriﬁed
sorted by ﬂow cytometry) before culture or puriﬁed
fter 3 days in culture. Activation with aAPC prefer-
ntially expanded CD4CD25 cells. Besides TCR
igure 5. CD8CD25 cells weakly suppressed the development
f DLI-induced GVHD in CD25/ BM chimeras. Survival (A)
nd body weights (B) were monitored for CD25/ chimeras co-
nfused with DLI and 5  106 (n 
 10) or 2.5  106 (n 
 9) ex
ivo–expanded CD8CD25 cells on day 28 after BMT. Controls
onsisted of CD25/ chimeras given DLI only (n 
 15).ignaling and CD28 co-stimulation, additional activa- (
56ion signals through 4-1BB/4-1BBL interactions may
ave driven activation and expansion, because aAPCs
ransfected with only CD32 and coated with anti-
D3 and CD28 mAbs were unable to efﬁciently drive
he expansion of CD4CD25 cells. Compared with
onventional T cells, signaling through CD28 seems
o be particularly important for the activation and
xpansion of CD4CD25 cells. We were able to
ttain a relatively modest 13-fold expansion of
D4CD25 cells by using aAPC. A variety of other
xpansion strategies for mouse CD4CD25 cells
ave been used [9,11,36], but they also resulted in only
odest cell expansions. In a recent report by Tang et
l. [37], up to 200-fold expansion of mouse
D4CD25 cells could be achieved with a combi-
ation of anti-CD3, anti-CD28, and IL-2, indicating
hat high levels of expansion are feasible. Thus, if
onditions are optimized, it seems that high levels of
xpansion can be achieved. We are currently modify-
ng our protocols in an effort to achieve better expan-
ion. CD28 co-stimulation has been shown to be crit-
cal for the generation and/or maintenance of
D4CD25 cells, and CD28 KO mice have few
D4CD25 cells [6,24,38,39]. Moreover, binding of
igure 6. Long-term persistence of fresh or ex vivo–expanded
D4CD25 cells given to suppress GVHD in vivo. Fresh
hy1.1 B6.PL CD25 cells or ex vivo–expanded CD4CD25
ells were tracked for in vivo persistence (A) and maintenance of
D25 expression (B) after co-infusion with DLI into CD25/
hy1.2 BM chimeras. Flow cytometric analysis of gated lympho-
ytes in the peripheral blood (PB), spleens (SP), and lymph nodes
LN) was performed at the indicated time points.
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Ex Vivo–Expanded CD4CD25 and CD8CD25Treg Cells in GVHD
BD28 alone by a CD28 superagonist has been shown
o efﬁciently expand rat CD4CD25 cells in vitro
nd in vivo [40]. Thus, continuous triggering through
D28 or other co-stimulatory molecules, including
-1BB, OX40, CD30, and glucocorticoid-induced tu-
or necrosis factor receptor, may be critical for main-
aining a stable CD4CD25 pool [17,29,41].
We observed approximately 50% suppression in
LR assays with freshly isolated CD25 cells at a
D25Treg/CD25
 responder ratio of 1:1 (Figure 1).
his is different from the results of many studies in
hich suppression of MLR reactivity by CD25 cells
t a similar ratio has often been greater than 90%. It
as been previously shown that strong T-cell signaling
an overcome CD25 cell-mediated suppression [42].
erhaps the reason for the 50% suppression in our
LR assays with freshly isolated CD25 cells was due
o the degree of histocompatibility disparity between
he stimulator and responder cells combined with our
se of dendritic cell–enriched stimulators in the MLR
ssays. We did consistently see enhanced suppression
hen alloantigen-activated-expanded CD25 cells
ere tested in the MLR assays (90%–98% suppression
bserved at a CD25 Treg/CD25
 responder ratio of
:1). Suppressive activity of CD4CD25 cells ex-
anded by CD32/4-1BBL–transfected aAPCs for 7
igure 7. Ex vivo–expanded CD4CD25 cells persisted and pro-
iferated only in CD25/, but not CD25/, BM chimeras after
o-infusion with DLI cells. Ex vivo–expanded CD4CD25 cells
ere tracked for in vivo persistence after co-infusion with DLI into
D25/ or CD25/ Thy1.2 BM chimeras.
igure 8. Ex vivo–expanded CD8CD25 cells quickly disap-
eared after infusion to suppress GVHD in vivo. Ex vivo–expanded
D8CD25 cells were tracked for in vivo persistence after co-
nfusion with DLI into CD25/ Thy1.2 BM chimeras at 1:1 or
:1 DLI/Treg ratios. r
B&MTays was intact when they were tested for suppression
n MLR assays, although recent reports have indicated
hat triggering the 4-1BBL/4-1BB pathway abrogates
he suppressive activity of CD4CD25 cells [33,43].
erhaps 4-1BBL/4-1BB signaling was no longer
resent in our system at the time of testing (day 7 of
ulture or later), because irradiated aAPC cells disap-
ear around day 5 of culture.
Unexpectedly, ex vivo–expanded CD8CD25
ells had suppressive activity in MLR assays equal to
hat of expanded CD4CD25 cells. This is consis-
ent with a ﬁnding that rat CD8CD25 cells were
uppressive in vitro, although the suppressive activity
as weaker than that of CD4CD25 cells [14]. A
uppressive population of fresh human CD8CD25
hymocytes has also been recently identiﬁed [44,45]. It
ould be interesting to test freshly isolated murine
D8CD25 cells for suppressive activity; however,
hese cells are present at such low numbers (5  104
er mouse) that it would be very difﬁcult to isolate
nough cells to assay their function in vitro. In con-
igure 9. Only Treg cells that maintained CD25 expression in vivo
ere suppressive in vitro. Persisting Thy1.1 Treg subsets
CD4CD25, CD425, and CD8) were isolated by ﬂow cyto-
etric sorting from the spleen (SP) and Lymph node (LN) of
yngeneic nude mice 6 months after adoptive transfer (A) or from
he SP and LN of DLI-treated CD25/ chimeras 15 weeks after
nfusion (B). The reisolated cells were then assayed for suppressive
ctivity in MLR assays. All curves are expressed as percentage of
ontrol MLR and represent the combined average values of 6 to 9
ndividual experiments. The raw data values for the control MLRs
anged from 8 to 10  104 CPM.
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7rast to CD8CD25 cells, CD4CD8CD25 cells
ailed to mediate suppression in vitro. Thus, within
he CD25 cell population, expanded/activated
D8CD25 and CD4CD25 cells, but not
D4CD8CD25 cells, exhibited suppressor func-
ion.
Ex vivo–expanded CD8CD25 cells only weakly
uppressed DLI-induced GVHD, although these
ells were as suppressive as ex vivo–expanded
D4CD25 cells in MLR assays. Infused
D8CD25 cells typically disappeared within 2
eeks after infusion. We speculate that this may be
ue to IL-2 withdrawal. Occasionally, CD8CD25
ells could be detected at low levels 2 weeks after
nfusion, and this was always seen in mice that devel-
ped less severe GVHD. Overall, our results suggest
hat therapeutic application of CD8CD25 cells
ay be limited.
Ex vivo–expanded CD4CD25 cells persisted in
ivo as efﬁciently as fresh CD4CD25 cells after
doptive transfer into syngeneic or allogeneic hosts,
hus suggesting that their maintenance can be driven
y self-antigens or alloAgs [46,47]. Interestingly, the
n vivo persistence of both fresh and ex vivo–expanded
D4CD25 seems to be under strict homeostatic
egulation, because infused CD4CD25 cells were
early undetectable in CD25/ BM chimeras,
hereas they persisted in CD25/ BM chimeras af-
er coadministration with DLI cells. Thus, exogenous
D4CD25 cells may compete with endogenous
D4CD25 cells for niches to colonize and survive.
his is consistent with the ﬁnding that exogenous
D4CD25 cells survived in IL-2R/ but not in
ild-type recipients [48]. Importantly, both fresh and
x vivo–expanded CD4CD25 cells effectively pre-
ented lethal acute GVHD. Thus far, the exact mech-
nism of GVHD protection/suppression in our model
s unclear, although multiple mechanisms have been
mplicated in different model systems in vitro and in
ivo [17,29,31,39,49].
It is unclear from our experiments whether the
nfused CD25 cells expanded in vivo after adoptive
ransfer, but the increasing percentages of infused
ells in nude recipients over time (Figure 1) suggested
hat they were expanding in these mice. However, in
LI-treated CD25/ BM chimeras, the infused
D4CD25 cells had already achieved maximum
evels in the peripheral blood by 2 weeks after infusion
Figure 7). We did not look at earlier time points in
hese mice, so if expansion of the infused cells did take
lace, it occurred during the ﬁrst 2 weeks after infu-
ion. The percentages of infused CD25 cells in the
eripheral blood and other lymphoid tissues (spleen
nd lymph nodes) of CD25/ BM chimeras were not
emarkably different from the percentages of CD25
ells in normal mice, suggesting that the infused cells
lled the vacant CD25 cell compartment and ex- a
58anded no further. We speculate that the relatively
arge numbers of infused CD25 cells (2.5  5  106
ells) rapidly ﬁlled the vacant CD25 compartment and
hat, therefore, vigorous homeostatic expansion was
ot required. The situation in the nude mice is differ-
nt because the total T-cell compartment is severely
eﬁcient. Perhaps homeostatic expansion would have
een more evident in the CD25/ BM chimeras had
e given smaller numbers of CD4CD25 cells.
Investigation is ongoing to deﬁne whether the
uppression mediated by CD4CD25 cells in our
LI model is alloAg speciﬁc. On the basis of recent
ndings that antigen-speciﬁc suppression can be me-
iated by CD4CD25 cells in vivo, we hypothesize
hat the suppression observed in our system is alloAg
peciﬁc [27,36,50,51]. It does not seem that adminis-
ration of expanded/activated CD4CD25 cells re-
ults in systemic immune suppression, because treated
ice in our experiments remained in good health and
ad no apparent increase in infections. Future studies
ill address whether fresh or ex vivo–expanded
D4CD25 cells can be used to treat ongoing DLI-
nduced GVHD and prevent its occurrence. On the
asis of recent data published by Jones et al. [11], it
eems promising that CD4CD25 cells, particularly
fter ex vivo expansion, could be used alone or in
ombination with other forms of immunosuppression
o target ongoing GVHD.
Interestingly, infused CD4CD25 cells are dy-
amic in vivo [46,52]. Maintenance of CD25 expres-
ion seems useful for deﬁning the suppressive subset
f infused CD4CD25 cells toward alloAgs, because
n our studies the cells that lost CD25 expression after
doptive transfer were no longer suppressive in MLR
ssays. This is consistent with a previous study show-
ng that transfer of the CD25 fraction, but not the
D25 fraction, of previously infused CD4CD25
ells (parked in lymphopenic mice for 7 weeks) could
ontrol CD4 cell expansion in secondary lym-
hopenic mice [52]. In our model, it is uncertain
hether the cells that lost CD25 expression were
uppressive against antigens other than alloAgs, be-
ause the proliferation of infused CD4CD25 cells
as likely driven by both alloAgs and self-antigens.
ther published data have shown that both CD25
nd CD25 cell fractions from CD4CD25 cells
reviously transferred to lymphopenic mice were still
apable of suppressing concanavalin A–stimulated T-
ell proliferation in vitro [46]. We will need to per-
orm similar studies to determine whether the same is
rue in our model.
In conclusion, the anergic status of fresh
D4CD25 cells can be overcome by strong acti-
ation signals induced through the TCR and CD28.
x vivo–expanded CD4CD25 cells migrate to pe-
ipheral lymphoid tissues, undergo dynamic changes,
nd can potently suppress the development of DLI-
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Bnduced GVHD. Thus, the therapeutic use of ex vivo–
xpanded CD4CD25 cells may be a feasible, non-
oxic modality for controlling GVHD in the clinic.
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